| Literature DB >> 24121307 |
Burçin Ünlü Ince1, Pim Cuijpers, Edith van 't Hof, Wouter van Ballegooijen, Helen Christensen, Heleen Riper.
Abstract
BACKGROUND: Turkish migrants living in the Netherlands have a high prevalence of depressive disorders, but experience considerable obstacles to accessing professional help. Providing easily accessible Internet treatments may help to overcome these barriers.Entities:
Keywords: Internet; depression; ethnic groups; psychotherapy; randomized controlled trial
Mesh:
Year: 2013 PMID: 24121307 PMCID: PMC3849840 DOI: 10.2196/jmir.2853
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1CONSORT flow diagram of the participation progress through the trial.
Demographic characteristics and baseline test scores at T0 (N=96).
| Demographic characteristics and baseline tests | Total (N=96) | Experimental group (n=49) | Control group (n=47) |
| |
| Age (years), mean (SD) | 35.2 (9.3) | 34.9 (8.9) | 35.6 (9.8) | .72 | |
| Gender (female), % (n) | 62 (59) | 65 (32) | 57 (27) | .43 | |
| Born in Turkey, % (n) | 91 (87) | 92 (45) | 89 (42) | .68 | |
| Long-term relationship, % (n) | 64 (61) | 71 (35) | 55 (26) | .10 | |
|
|
|
|
|
| |
|
| Low | 27 (26) | 35 (17) | 19 (9) |
|
|
| Middle | 41 (39) | 31 (15) | 51 (24) |
|
|
| High | 32 (31) | 35 (17) | 30 (14) | .09 |
| Preference for Turkish language, % (n) | 89 (85) | 88 (43) | 89 (42) | .81 | |
|
|
|
|
|
| |
|
| Internet | 78 (75) | 78 (38) | 79 (37) |
|
|
| Internet through Facebook | 99 (74) | 100 (38) | 97 (36) |
|
|
| Newspaper | 1 (1) | 0 (0) | 2 (1) |
|
|
| Magazine | 1 (1) | 2 (1) | 0 (0) |
|
|
| Friends or family | 6 (6) | 10 (5) | 2 (1) |
|
|
| Other | 14 (13) | 10 (5) | 17 (8) | .89 |
| Employed, % (n) | 52 (49) | 45 (22) | 57 (27) | .22 | |
|
|
|
|
|
| |
|
| Privacy/anonymity | 23 (22) | 22 (11) | 23 (11) |
|
|
| Flexibility | 62 (59) | 51 (25) | 72 (34) |
|
|
| Other | 16 (15) | 27 (13) | 4 (2) | .01 |
|
|
|
|
|
| |
|
| Physical complaints | 7 (7) | 8 (4) | 6 (3) |
|
|
| Psychological complaints | 10 (10) | 8 (4) | 13 (6) |
|
|
| Physical and psychological complaints | 67 (64) | 71 (35) | 62 (29) |
|
|
| None | 16 (15) | 12 (6) | 19 (9) | .65 |
|
|
|
|
|
| |
|
| Depression (CES-D) | 29.9 (9.6) | 29.6 (9.2) | 30.1 (10.1) | .79 |
|
| Anxiety (HADS) | 13.0 (4.1) | 13.3 (4.3) | 12.7 (3.9) | .52 |
|
| Somatization (SCL-90) | 30.0 (8.6) | 31.0 (9.2) | 29.0 (8.0) | .25 |
|
| Quality of life (EQ-VAS)b | 60.4 (21.2) | 57.7 (21.5) | 63.14 (20.8) | .27 |
aCES-D was analyzed with a 1-tailed t test. The other tests were analyzed with a 2-tailed t test.
bTotal: N=74; experimental group: n=38; control group: n=36. This item was the last of the assessment, which was not filled in by every participant.
Study outcomes at posttest including posttest between-group effect size (Cohen’s d): intention-to-treat analysis.
| Outcome and group | Pretest | Posttest |
| Mean difference | Cohen’s | ||||
|
| n | Mean | n | Mean |
|
|
| ||
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 49 | 29.6 | 49 | 23.0 |
|
|
|
|
|
| Control group | 47 | 30.1 | 47 | 27.2 | .07 | –4.25 | 0.37 (–0.03, 0.78) |
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 49 | 13.3 | 49 | 11.0 |
|
|
|
|
|
| Control group | 47 | 12.7 | 47 | 11.7 | .23 | –0.76 | 0.25 (–0.16, 0.65) |
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 49 | 31.0 | 49 | 28.1 |
|
|
|
|
|
| Control group | 47 | 29.0 | 47 | 28.0 | .48 | 0.13 | 0.15 (–0.26, 0.55) |
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 38 | 57.7 | 38 | 65.4 |
|
|
|
|
|
| Control group | 36 | 63.1 | 36 | 65.7 | .48 | –0.28 | 0.15 (–0.26, 0.55) |
Clinically significant change analyses of depression tested by the CES-D.
| Clinically significant change analyses | Posttest, n (%) |
| Follow-up, n (%) |
| |||
|
| Experimental group | Control group |
| Experimental group | Control group |
| |
|
|
|
|
|
|
|
| |
|
| Recovery | 15.6 (32.9) | 4.3 (9.4) | .02 |
|
|
|
|
| Improvement | 18.5 (37.8) | 9.4 (20.0) | .07b |
|
|
|
|
| Clinically significant change | 11.8 (24.9) | 2.6 (5.7) | .05 |
|
|
|
|
|
|
|
|
|
|
| |
|
| Recovery | 10 (38.5) | 1 (3.3) | <.001 | 6 (46.2) | 3 (12.5) | .01 |
|
| Improvement | 12 (46.2) | 4 (13.3) | .01 | 7 (53.8) | 4 (16.7) | .01 |
|
| Clinically significant change | 6 (23.1) | 1 (3.3) | .01 | 5 (38.5) | 2 (8.3) | .01 |
aRecovery was defined as having a CES-D score below 16. Improvement was defined as having a reliable change if the individual RCI is greater than 1.96. Clinically significant change was determined if both recovery and improvement took place.
bFor this analysis, the P value of the chi-square analysis is provided.
Study outcomes of participants at posttest and follow-up including between-group effect size (Cohen’s d): per protocol (n=30).
| Per protocol | Posttest | 4-month follow-up | ||||||||
|
| n | Mean (SD) |
| Cohen’s | n | Mean (SD) |
| Cohen’s | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 6 | 15.3 (9.9) |
|
| 6 | 19.0 (13.9) |
|
|
|
|
| Control group | 24 | 29.5 (8.8) | <.001 | 1.68 (0.69, 2.67) | 24 | 30.1 (11.3) | .02 | 1.13 (0.19, 2.07) |
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 6 | 7.3 (2.9) |
|
| 6 | 7.8 (4.9) |
|
|
|
|
| Control group | 24 | 12.4 (3.5) | <.001 | 1.48 (0.51, 2.45) | 24 | 12.1 (3.7) | .01 | 1.26 (0.31, 2.21) |
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 6 | 18.8 (6.2) |
|
| 6 | 19.2 (6.9) |
|
|
|
|
| Control group | 24 | 28.5 (8.1) | .001 | 0.37 (0.41, 2.33) | 24 | 28.5 (8.5) | .01 | 1.27 (0.32, 2.22) |
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 5 | 79.4 (28.9) |
|
| 5 | 82.3 (23.0) |
|
|
|
|
| Control group | 20 | 63.6 (21.7) | .07 | 0.95 (–0.06, 1.97) | 20 | 66.4 (23.2) | .11 | 0.83 (–0.18, 1.84) |
Study outcomes of participants at posttest and follow-up including follow-up between-group effect size (Cohen’s d): completers only (n=56).
| Completers only | Posttest | 4-month follow-up | ||||||||
|
| n | Mean (SD) |
| Cohen’s | n | Mean (SD) |
| Cohen’s | ||
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 26 | 21.38 (10.5) |
|
| 13 | 21.23 (10.79) |
|
|
|
|
| Control group | 30 | 28.27 (8.71) | .01 | 0.72 (0.17, 1.26) | 24 | 30.08 (11.27) | .01 | 0.94 (0.23, 1.65) |
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 26 | 10.54 (4.00) |
|
| 13 | 9.69 (4.92) |
|
|
|
|
| Control group | 30 | 11.87 (3.76) | .10 | 0.45 (–0.08, 0.98) | 24 | 12.08 (3.67) | .05 | 0.69 (0.00, 1.39) |
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 26 | 26.00 (10.02) |
|
| 13 | 25.31 (9.78) |
|
|
|
|
| Control group | 30 | 27.70 (7.76) | .24 | 0.32 (–0.21, 0.85) | 24 | 28.54 (8.52) | .15 | 0.51 (–0.18, 1.19) |
|
|
|
|
|
|
|
|
|
|
| |
|
|
| Experimental group | 19 | 70.95 (19.52) |
|
| 10 | 78.80 (22.50) |
|
|
|
|
| Control group | 23 | 64.17 (21.54) | .15 | 0.46 (–0.16, 1.07) | 19 | 66.42 (23.19) | .13 | 0.61 (–0.17, 1.39) |